title: STEP: simplified treatment of the enlarged prostate.
abstract: We propose a simple and practical approach to the identification, evaluation and treatment of lower urinary tract symptoms (LUTS) resulting from an enlarging and obstructive prostate. The proposed Simplified Treatment for Enlarged Prostate (STEP) plan is a logical guide to patient management by the primary care provider (PCP). Symptoms of enlarged prostate (EP) are common and may frequently progress into a condition with profound adverse effects on quality of life. Despite the high prevalence, EP is underdiagnosed and undertreated. This situation may result from patient- and provider-related issues. Assessment of symptoms of EP should be initiated with a discussion of LUTS. Evaluation includes a focused history, physical examination and selected laboratory tests. Certain factors put the symptomatic patient at risk for disease progression; however, not all factors can be readily evaluated in the PCP setting. The serum prostate-specific antigen (PSA) level acts both as an indicator of prostatic size and a screening tool for prostatic cancer, and thereby provides an important tool for PCPs. The STEP plan is a logical guide to patient management. Step 1, watchful waiting, is appropriate in patients with symptoms that are not bothersome. If symptoms cause bother, the initiation of an alpha-blocker (AB) in step 2, provides relatively rapid symptom improvement. Patients with bothersome symptoms and a PSA > or = 1.5 ng/ml are at risk for progression and consideration should be given to combination treatment with an AB and a 5alpha-reductase inhibitor (step 3). Patients with refractory symptoms should be referred to a urologist (step 4). Identification, evaluation and management of EP are within the domain of the primary care setting. The STEP approach provides a simple and practical framework for PCPs to manage most men with symptoms of EP.
authors.affiliation: Department of Family Medicine, Mid-Michigan Health Centers, Allegiance Health System, Jackson, MI, USA. matttoren@yahoo.com
authors.forename: M T
authors.initials: MT
authors.lastname: Rosenberg
authors.forename: M M
authors.initials: MM
authors.lastname: Miner
authors.forename: P A
authors.initials: PA
authors.lastname: Riley
authors.forename: D R
authors.initials: DR
authors.lastname: Staskin
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000628:therapy*; D053448:Prostatism / Q000209:etiology / Q000628:therapy; D011788:Quality of Life; D012017:Referral and Consultation; D057832:Watchful Waiting
chemical_list: D058891:5-alpha Reductase Inhibitors; D000318:Adrenergic beta-Agonists